[{"id":"722e7e39-2b2e-4e81-be40-58b1e321be96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043713","created_at":"2023-09-21T15:10:30.740Z","updated_at":"2025-02-25T13:41:44.027Z","phase":"Phase 1","brief_title":"Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations","source_id_and_acronym":"NCT06043713","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 02/09/2026","study_completion_date":" 02/09/2026","last_update_posted":"2025-02-21"},{"id":"f183e140-987d-476d-a6b5-4df9e4ffb873","acronym":"TCR-T","url":"https://clinicaltrials.gov/study/NCT05417932","created_at":"2022-06-14T22:56:30.934Z","updated_at":"2025-02-25T14:08:55.469Z","phase":"Phase 1/2","brief_title":"A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma","source_id_and_acronym":"NCT05417932 - TCR-T","lead_sponsor":"SCG Cell Therapy Pte. Ltd.","biomarkers":" STMN2","pipe":"","alterations":" ","tags":["STMN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCG101"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-18"},{"id":"aa0ea678-0fd7-41d5-9cac-558568133e0c","acronym":"EBVision","url":"https://clinicaltrials.gov/study/NCT04554914","created_at":"2021-01-18T21:46:31.475Z","updated_at":"2025-02-25T15:11:41.557Z","phase":"Phase 2","brief_title":"A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases","source_id_and_acronym":"NCT04554914 - EBVision","lead_sponsor":"Atara Biotherapeutics","biomarkers":" CD20","pipe":" | ","alterations":" CD20 negative","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tab-cel (tabelecleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 07/14/2021","start_date":" 07/14/2021","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-13"},{"id":"abcc9d45-86e5-4f8d-9765-fdc49b92af3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06028074","created_at":"2023-09-07T16:09:55.474Z","updated_at":"2025-02-25T15:20:49.574Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies","source_id_and_acronym":"NCT06028074","lead_sponsor":"Georgiamune Inc","biomarkers":" LAG3","pipe":"","alterations":" ","tags":["LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GIM-122"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 12/12/2023","start_date":" 12/12/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-12"},{"id":"dac7a960-3256-4848-beff-89eb396b20cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06822998","created_at":"2025-02-25T15:15:53.738Z","updated_at":"2025-02-25T15:15:53.738Z","phase":"Phase 1","brief_title":"HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors","source_id_and_acronym":"NCT06822998","lead_sponsor":"HighField Biopharmaceuticals Corporation","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-12"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"57a461d0-704c-401d-b50c-fda397e12376","acronym":"","url":"https://clinicaltrials.gov/study/NCT06617000","created_at":"2025-02-26T14:59:12.446Z","updated_at":"2025-02-26T14:59:12.446Z","phase":"Phase 1","brief_title":"A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related","source_id_and_acronym":"NCT06617000","lead_sponsor":"SCG Cell Therapy Pte. Ltd.","biomarkers":" STMN2","pipe":"","alterations":" ","tags":["STMN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCG101"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 10/25/2022","start_date":" 10/25/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-09-27"},{"id":"cb3cb1db-2e3e-4730-8a0c-9a0d27e26ede","acronym":"","url":"https://clinicaltrials.gov/study/NCT06471673","created_at":"2025-02-26T10:47:22.224Z","updated_at":"2025-02-26T10:47:22.224Z","phase":"Phase 1/2","brief_title":"A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer","source_id_and_acronym":"NCT06471673","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" PD-L1 • PD-L2 • PRAME","pipe":"","alterations":" ","tags":["PD-L1 • PD-L2 • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • cyclophosphamide • Bria-OTS"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 05/29/2024","start_date":" 05/29/2024","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2024-08-26"},{"id":"3ffb83b9-b7f6-4a1b-b219-82bb668c8ae7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03847519","created_at":"2021-01-18T18:59:33.778Z","updated_at":"2024-07-02T16:34:59.300Z","phase":"Phase 1/2","brief_title":"Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03847519","lead_sponsor":"Advaxis, Inc.","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK translocation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • OST-503"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 02/22/2022","primary_completion_date":" 02/22/2022","study_txt":" Completion: 02/22/2022","study_completion_date":" 02/22/2022","last_update_posted":"2024-06-04"},{"id":"6e3f6be3-6b8b-473c-9f18-8ce3111ed3d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05424822","created_at":"2022-06-22T00:55:25.938Z","updated_at":"2024-07-02T16:35:01.349Z","phase":"Phase 1","brief_title":"A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT05424822","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JNJ-8543"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2024-05-23"},{"id":"5c9805aa-f9a6-41fd-96e7-7f8d0f28c893","acronym":"","url":"https://clinicaltrials.gov/study/NCT05533697","created_at":"2022-09-09T15:55:01.162Z","updated_at":"2024-07-02T16:35:07.372Z","phase":"Phase 1/2","brief_title":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05533697","lead_sponsor":"ModernaTX, Inc.","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • mRNA-4359"],"overall_status":"Recruiting","enrollment":" Enrollment 194","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 12/08/2027","primary_completion_date":" 12/08/2027","study_txt":" Completion: 12/08/2027","study_completion_date":" 12/08/2027","last_update_posted":"2024-04-26"},{"id":"e17dace3-40cf-43d5-bbae-779980aa63c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02938299","created_at":"2022-04-11T23:53:12.156Z","updated_at":"2024-07-02T16:35:10.976Z","phase":"Phase 3","brief_title":"Neoadjuvant L19IL2/L19TNF- Pivotal Study","source_id_and_acronym":"NCT02938299","lead_sponsor":"Philogen S.p.A.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nidlegy (darleukin/fibromun) • darleukin (L19IL2)"],"overall_status":"Recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-08"},{"id":"d1a7b79d-736e-4b7f-8ef7-b4d26c7f7408","acronym":"","url":"https://clinicaltrials.gov/study/NCT05544968","created_at":"2022-09-19T14:56:41.267Z","updated_at":"2024-07-02T16:35:13.132Z","phase":"Phase 1/2","brief_title":"CD30biAb-AATC for CD30+ Malignancies","source_id_and_acronym":"NCT05544968","lead_sponsor":"Medical College of Wisconsin","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD30 biAb-AATC"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-03-22"},{"id":"237b354a-5aa6-4026-9efe-63dba3502553","acronym":"","url":"https://clinicaltrials.gov/study/NCT05451849","created_at":"2022-07-11T11:54:54.962Z","updated_at":"2024-07-02T16:35:16.022Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer","source_id_and_acronym":"NCT05451849","lead_sponsor":"TCR2 Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TC-510"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 06/21/2022","start_date":" 06/21/2022","primary_txt":" Primary completion: 10/30/2028","primary_completion_date":" 10/30/2028","study_txt":" Completion: 10/30/2028","study_completion_date":" 10/30/2028","last_update_posted":"2024-03-06"},{"id":"f8516452-54df-4277-8f56-8aa72d1fb00e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907852","created_at":"2021-01-18T19:14:14.258Z","updated_at":"2025-02-25T14:28:16.858Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","source_id_and_acronym":"NCT03907852","lead_sponsor":"TCR2 Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 11/02/2028","primary_completion_date":" 11/02/2028","study_txt":" Completion: 11/02/2028","study_completion_date":" 11/02/2028","last_update_posted":"2024-03-06"},{"id":"e41a0274-04d0-4274-aa51-19e90a49274f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03983954","created_at":"2021-01-18T19:35:39.578Z","updated_at":"2025-02-25T15:08:38.440Z","phase":"Phase 1","brief_title":"Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT03983954","lead_sponsor":"NeoTX Therapeutics Ltd.","biomarkers":" HER-2 • ER • TPBG","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • TPBG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/10/2019","start_date":" 10/10/2019","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-02-22"},{"id":"f7ccd756-4413-4530-bc65-1188b9dc3cbc","acronym":"DIAL","url":"https://clinicaltrials.gov/study/NCT03038672","created_at":"2021-01-18T14:57:44.271Z","updated_at":"2024-07-02T16:35:20.479Z","phase":"Phase 2","brief_title":"Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas","source_id_and_acronym":"NCT03038672 - DIAL","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • TMB • BCL2 • BCL6 • CD27 • IRF4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD27 expression","tags":["ALK • TMB • BCL2 • BCL6 • CD27 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD27 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • varlilumab (CDX 1127) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 05/26/2023","primary_completion_date":" 05/26/2023","study_txt":" Completion: 10/25/2024","study_completion_date":" 10/25/2024","last_update_posted":"2024-02-07"},{"id":"dbd8060f-f9fc-4e93-8baf-7895d90d342a","acronym":"Mel-65","url":"https://clinicaltrials.gov/study/NCT03617328","created_at":"2021-01-29T07:17:48.889Z","updated_at":"2024-07-02T16:35:20.701Z","phase":"Phase 1/2","brief_title":"Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma","source_id_and_acronym":"NCT03617328 - Mel-65","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e varlilumab (CDX 1127) • Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 11/13/2018","start_date":" 11/13/2018","primary_txt":" Primary completion: 01/19/2024","primary_completion_date":" 01/19/2024","study_txt":" Completion: 01/19/2024","study_completion_date":" 01/19/2024","last_update_posted":"2024-02-06"},{"id":"804c573f-8c22-4ca6-9bc7-e76c192b00c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02950259","created_at":"2021-01-18T14:29:26.884Z","updated_at":"2024-07-02T16:35:21.864Z","phase":"Phase 1","brief_title":"Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)","source_id_and_acronym":"NCT02950259","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" HER-2","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • citoplurikin (IRX-2) • cyclophosphamide intravenous • omeprazole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 05/13/2019","primary_completion_date":" 05/13/2019","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-01-30"},{"id":"37ba8d01-7c78-43cc-81e1-59e78827f9d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04367675","created_at":"2021-01-18T21:06:34.302Z","updated_at":"2024-07-02T16:35:32.189Z","phase":"Phase 1b","brief_title":"INO 5401 Vaccination in BRCA1/2 Mutation Carriers","source_id_and_acronym":"NCT04367675","lead_sponsor":"University of Pennsylvania","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INO-5401 • rocakinogene sifuplasmid (INO-9012)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-23"},{"id":"f006991a-381f-4af1-aee4-1aabbfd0f738","acronym":"","url":"https://clinicaltrials.gov/study/NCT06088459","created_at":"2023-10-18T16:14:28.892Z","updated_at":"2024-07-02T16:35:32.927Z","phase":"Phase 1","brief_title":"NWRD06 DNA Plasmid for HCC After Radical Resection","source_id_and_acronym":"NCT06088459","lead_sponsor":"Newish Technology (Beijing) Co., Ltd.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-18"},{"id":"522ce461-bd5b-48fe-83ce-bfdef14e9b4b","acronym":"GEN001-201","url":"https://clinicaltrials.gov/study/NCT05419362","created_at":"2022-06-15T16:54:51.189Z","updated_at":"2025-02-25T16:17:49.248Z","phase":"Phase 2","brief_title":"GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer","source_id_and_acronym":"NCT05419362 - GEN001-201","lead_sponsor":"Genome \u0026 Company","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • GEN-001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 04/07/2022","start_date":" 04/07/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-17"},{"id":"463880b8-db67-43d7-bf2e-e66e4dd193ce","acronym":"RiVa","url":"https://clinicaltrials.gov/study/NCT03307746","created_at":"2021-01-18T16:20:12.078Z","updated_at":"2024-07-02T16:35:33.664Z","phase":"Phase 2a","brief_title":"A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma","source_id_and_acronym":"NCT03307746 - RiVa","lead_sponsor":"University Hospital Southampton NHS Foundation Trust","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • varlilumab (CDX 1127)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 11/23/2017","start_date":" 11/23/2017","primary_txt":" Primary completion: 02/18/2021","primary_completion_date":" 02/18/2021","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2023-10-12"},{"id":"d518557a-eea1-4a79-acfc-244bfd4c8285","acronym":"","url":"https://clinicaltrials.gov/study/NCT06037018","created_at":"2023-09-14T15:13:31.451Z","updated_at":"2024-07-02T16:35:36.987Z","phase":"Phase 1","brief_title":"Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies","source_id_and_acronym":"NCT06037018","lead_sponsor":"CytoCares Inc","biomarkers":" CD8 • CD4","pipe":" | ","alterations":" CD19 positive","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 08/07/2023","start_date":" 08/07/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2023-09-14"}]